Vertex Pharmaceuticals, Inc. (VRTX) Blows Up Q3 Estimates
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $546.12 -2.12%
EPS Growth %: 0.0%
Financial Fact:
Restructuring expense: 8K
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: 0.0%
Financial Fact:
Restructuring expense: 8K
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q3 EPS of $0.70, $0.53 better than the analyst estimate of $0.17. Revenue for the quarter came in at $659.2 million versus the consensus estimate of $343.42 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Adjust Monthly US Director's Cut List
- John Wiley & Sons, Inc. (WLY) Tops Q1 EPS by 4c ; Offers Guidance
- Morgan Stanley Resumes Vertex (VRTX) at Overweight
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
